TAS2R38 and early-onset autosomal dominant Alzheimer disease: Identifying such a genetic connection could support developing new drugs or repurposing existing ones for AD treatment.<h4>Methods</h4>In this work, we examined the relationship between allele counts of TAS2R38 taster variants and AD risk using linear mixed-effects models, utilizing genetic, clinical, and biomarker data from the Alzheimer's Disease Neuroimaging Initiative (ADNI).